David's extensive experience comprises venture capital, private equity and executive management, mainly in the healthcare arena.
Until 2014, David was CEO and Board Member at XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL), where he recovered the company from practically bankruptcy via M&A, in-licensing, fund raising, takeovers to being a late-stage drug development company.
David has also served as a Vice President of Eurocom Investments LP, a private equity fund. Prior to that, Mr. Grossman was a Senior Analyst at Israel Health Care Ventures (IHCV), an Israeli leading healthcare venture capital fund.
David was Chairman of the Board at Algomizer Ltd. (TASE: ALMO) and Board member in several public companies traded on NASDAQ, AIM and TASE, such as, Rosetta Green Ltd. (TASE: GFC), Proteologics Ltd. (TASE: PRTL), InterCure Ltd. (TASE: INCR), Bio Light Israeli Life Science Investments Ltd. (TASE: BOLT), and Gilat Satcom Ltd. (AIM: GLT).
He currently serves as a board member at AIT Pharmaceuticals Ltd, Cellect Biotechnology Ltd. (NASDAQ: APOP, TASE: CLBD) and Amnis Therapeutics Ltd. (TASE: AMNS).
A native of the United Kingdom, David holds a BA in Business Administration and Finance from the Interdisciplinary Center (IDC) in Israel.